Caris Life Sciences/$CAI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Caris Life Sciences
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
- Ticker
- $CAI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,846
- Headquarters
- Irving, United States
- Website
- www.carislifesciences.com
CAI Metrics
BasicAdvanced
$7.5B
78.11
$0.33
-
-
Price and volume
Market cap
$7.5B
52-week high
$36.50
52-week low
$14.19
Average daily volume
3.7M
Financial strength
Current ratio
6.715
Quick ratio
5.667
Long term debt to equity
0.714
Total debt to equity
0.715
Interest coverage (TTM)
3.28%
Profitability
EBITDA (TTM)
162.435
Gross margin (TTM)
69.27%
Net profit margin (TTM)
9.16%
Operating margin (TTM)
13.35%
Effective tax rate (TTM)
1.55%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
7.81%
Return on equity (TTM)
17.19%
Valuation
Price to earnings (TTM)
78.111
Price to revenue (TTM)
7.033
Price to book
11.67
Price to tangible book (TTM)
12.03
Price to free cash flow (TTM)
254.996
Free cash flow yield (TTM)
0.39%
Free cash flow per share (TTM)
0.102
Growth
Revenue change (TTM)
61.48%
Earnings per share change (TTM)
-105.14%
What the Analysts think about CAI
Analyst ratings (Buy, Hold, Sell) for Caris Life Sciences stock.
Analyst projections of the future price of Caris Life Sciences stock.
Bulls say / Bears say
Third-quarter revenue rose 27% and clinical cases grew 21%; Caris also lifted its 2026 revenue outlook to 28–29% growth. The quarter returned to GAAP profit, supporting the case that demand is translating into scale. (Caris Life Sciences)
Caris has expanded its portfolio from test selection into treatment monitoring, with a tumour-informed MRD test due in December. These offerings use existing platforms and oncology relationships, giving the company a chance to sell more services through its established channels. (Caris Life Sciences)
The preliminary 2027 Medicare fee schedule raises the Caris Assure rate to $5,250 from $3,650, a 44% increase. If finalised, the higher rate could support blood-test revenue and realised pricing from 2027. (Stock Analysis)
Cash generation weakened sharply: operating cash flow was negative $22.2 million and free cash flow was negative $39.7 million in the quarter. Caris says commercial expansion, launch inventory and research spending drove the outflow, so growth is not yet converting consistently into cash. (Caris Life Sciences)
Operating expenses rose 42% year on year to $163 million, well ahead of 27% revenue growth, as the company increased sales, research and marketing spending. If new products do not scale, this cost growth could hold back operating leverage. (Caris Life Sciences)
The commercial payoff from newer tests remains uncertain: Caris gave no early sales figures for Detect, while Confirm is planned for a limited introduction as the company seeks reimbursement coverage. Slow adoption or coverage could leave those launches contributing less than hoped. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
CAI Financial Performance
Revenues and expenses
CAI Earnings Performance
Company profitability
Upcoming events
No upcoming events
CAI News
AllArticlesVideos
Caris Life Sciences Q3 Earnings Call Highlights
MarketBeat2 days ago
IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
Investors Business Daily1 month ago
Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice
Proactive Investors2 months ago
Funds containing CAI
AllUSDEURGBP
Fund name | Fund size | $CAI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.59% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.59% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.44% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.44% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.44% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.